PHO

The Week

Agilent Technologies (A) slipped 0.46% this week to close at $173.96, while the S&P 500 rose 2.51% over the same stretch — putting the stock about 2.97 percentage points behind the index. The path was front-loaded: Monday (Nov 9) opened higher and touched $180.99 before ending at $180.17, Tuesday (Nov 10) eased to $177.88, and Wednesday (Nov 11) printed the week’s high at $181.265 but faded into the close at $176.95. Thursday (Nov 12) and Friday (Nov 13) then slid in tandem, with the weekly low at $170.71. Weekly amplitude reached 5.98%, and volume ran about 16.68% below the 60-day median — a quiet tape overall.

Key Events

The week carried two product-adjacent notes and one conference appearance. On Tuesday (Nov 10), a market bulletin noted that Agilent’s Monday gain lagged rivals on the same day. Thursday (Nov 12) brought discussion of the company’s Pan Heme haematology panel launch and what it might mean for investors. Friday (Nov 13) saw the company participate in the 9th Annual Evercore Healthcare Conference — a routine investor event. There was no earnings release, major partnership, or regulatory item this week, and the late-week pullback overlapped with softer relative performance against peers; the two are better described as coinciding rather than one causing the other.

Analyst Ratings

Among 22 institutions covering the name, 12 rate it buy, 3 rate it overweight, 7 rate it hold, and none rate it underweight or sell. The consensus rating is buy, with a consensus target of $182.05 — about 4.65% above the latest close. Target prices span $155 to $200, so dispersion remains visible. Within the life sciences tools and services industry, the stock ranks 4th out of 54 names — toward the top end. The overall tone is constructive, though the wide target band suggests analysts do not agree uniformly on the next leg.

The Week Ahead

The earnings calendar is the main anchor. Agilent reports fiscal Q4 2026 results after the close on Nov 23, with consensus estimates pointing to EPS of $1.5875 and revenue of $1.989 billion. Before that, a run of macro releases will settle expectations: the New York Fed manufacturing index on Nov 16 (prior 25.5, forecast 18), and on Nov 17 retail sales (prior 0.8, forecast 0.2), industrial production (prior 0.7, forecast 0.1), and related prints. Big deviations from forecasts could shift risk appetite. The bigger question is whether the company’s numbers and next-year guidance align with the current buy-rated stance.

In Short

The signals this week sit in tension. The consensus among institutions is buy with a target above spot, while the stock trades at rich multiples — roughly 34x P/E and 6.66x P/B. Yet the latest trading day’s fund flow shows large and mid-lot buying alongside even larger small-lot inflows, with direction mixed rather than a single coordinated push. The price itself edged lower and lagged the market on shrinking volume, hinting at a wait-and-see mood. The next test is earnings and the macro data: whether results give the current rating profile something to anchor on.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.